|Day Low/High||32.75 / 34.09|
|52 Wk Low/High||22.51 / 61.69|
The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.
CMPS may be a company representing the true cannabis 2.0. The irony in that is it isn't a cannabis company but rather a play on psilocybin.
Dealmaking is going strong and looks set to continue as mental health becomes a key investment theme going forward.
Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target.
Fresh off IPO, company sees mushrooming opportunity in psilocybin.